Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruixiao Lu

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
JCO Precision Oncology|May 9, 2024
Using Radiomics in Cancer ManagementShivaani Kummar, Ruixiao Lu
Urology|June 12, 2020
The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate CancerJennifer Cullen, Huai-Ching Kuo, Jun Shan, et al.
JCO Precision Oncology|May 26, 2021
GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific MortalityMichael A Brooks, Lewis Thomas, Cristina Magi-Galluzzi, et al.
Reviews in Urology|November 12, 2016
Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate ScoreDavid Albala, Michael J Kemeter, Phillip G Febbo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Human in vivo dose-response to controlled, low-dose low linear energy transfer ionizing radiation exposureZelanna Goldberg, David M Rocke, Chad Schwietert, et al.
BMC Cancer|June 19, 2016
A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancerRangaswamy Govindarajan, James Posey, Calvin Y Chao, et al.
Urologic Oncology|November 26, 2021
Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomyMichael A Brooks, Lewis Thomas, Cristina Magi-Galluzzi, et al.
Clinical and Translational Science|November 28, 2024
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study designSibel Ucpinar, Joyce K Kwan, Joshua D Hoffman, et al.
Urology|January 7, 2019
A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and UtilityScott Eggener, Lawrence I Karsh, Tim Richardson, et al.
The Journal of Urology|January 25, 2021
Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate CancerJennifer Cullen, Julie A Lynch, Eric A Klein, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
JCO Precision Oncology|May 9, 2024
Using Radiomics in Cancer ManagementShivaani Kummar, Ruixiao Lu
Urology|June 12, 2020
The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate CancerJennifer Cullen, Huai-Ching Kuo, Jun Shan, et al.
JCO Precision Oncology|May 26, 2021
GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific MortalityMichael A Brooks, Lewis Thomas, Cristina Magi-Galluzzi, et al.
Reviews in Urology|November 12, 2016
Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate ScoreDavid Albala, Michael J Kemeter, Phillip G Febbo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Human in vivo dose-response to controlled, low-dose low linear energy transfer ionizing radiation exposureZelanna Goldberg, David M Rocke, Chad Schwietert, et al.
BMC Cancer|June 19, 2016
A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancerRangaswamy Govindarajan, James Posey, Calvin Y Chao, et al.
Urologic Oncology|November 26, 2021
Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomyMichael A Brooks, Lewis Thomas, Cristina Magi-Galluzzi, et al.
Clinical and Translational Science|November 28, 2024
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study designSibel Ucpinar, Joyce K Kwan, Joshua D Hoffman, et al.
Urology|January 7, 2019
A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and UtilityScott Eggener, Lawrence I Karsh, Tim Richardson, et al.
The Journal of Urology|January 25, 2021
Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate CancerJennifer Cullen, Julie A Lynch, Eric A Klein, et al.
Pageof 2